Electrophysiology Scientific Core 2
Electrophysiology Scientific Core 2
批准号:
10646347
负责人:
KENNETH LAURITA
金额:
$26.24万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2027-06-30
关键词:
Action PotentialsAgeApplications GrantsArrhythmiaAtrial FibrillationCell physiologyClinicalComplementCritiquesDataData CollectionDiagnosisDissociationDoctor of PhilosophyDyesElectrocardiogramElectrophysiology (science)EnsureEquipmentExperimental DesignsFluorescence MicroscopyFunctional disorderFura-2GeneticGenomicsGoalsHeartHeart AtriumHuman ResourcesIn SituIncidenceIndividualIon ChannelKineticsLeadLeft atrial structureLinkMapsMeasuresMembrane PotentialsMetabolicMethodologyMethodsMitochondriaMolecularMonitorMusMuscle CellsObesityOpticsOrganizational EfficiencyOutcomePerfusionPhenotypePopulationPredispositionPreparationPreventiveProceduresProductionProgram Research Project GrantsPropertyReactive Oxygen SpeciesRegulationReproducibilityResearch InstituteResearch PersonnelResolutionRight atrial structureRiskSamplingScientistServicesStrokeSystemTechniquesTechnologyTestingTherapeuticcardiac tissue engineeringcardiovascular risk factorclinical applicationcost effectivecost efficientdesigndrug discoveryexperimental studygenome wide association studyinnovationmitochondrial membranemortalitypatch clampprogramsresponsestressortherapeutically effectivevoltagevoltage sensitive dye
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SC2 PROJECT SUMMARY
Atrial fibrillation (AF) is the most common arrhythmia and a major risk factor for cardiovascular mortality and
stroke. Incidence of AF is further increasing due to the rise in obesity and age of the population, factors closely
related to AF risk and progression. Despite significant advances in AF diagnosis and management, treatment
and clinical outcomes remain poor and more than a decade has passed since the last AF drug discovery. The
overall goal of this PPG application is to use genetic/genomic findings to identify preventative and therapeutic
strategies for AF and develop them towards clinical application. Our central hypothesis is that increasing the
understanding of molecular mechanisms involved in genetic, metabolic and structural changes in the atria will
allow us to pinpoint possible targets for safer and more effective therapeutic strategies. Scientific Core 2
(SC2): Electrophysiology Core will support the overall goal of the PPG and test program hypotheses as
follows: Aim 1. Routine and reliable acquisition of ECG data for serial assessment of AF progression and
burden, Aim 2: Optical mapping of mice atria and engineered heart tissue (EHT) for linking cellular
pathophysiology with mechanisms of AF, Aim 3: Enzymatic isolation of mouse atrial myocytes for
electrophysiologic, ion channel and Ca2+ cycling studies. Collectively, the isolated myocyte studies combined
with optical mapping will provide important mechanistic links between cellular pathophysiology, AF in situ, and
the progresion of AF in serial ECGs. We will leverage the capabilities and expertise of this Core to allow
Project investigators to systematically integrate electrophysiological and cellular findings with genetic
observations. This allows an assessment of differences in susceptibility of the atria to metabolic or other
stressors that Projects will be studying as important contributors to AF initiation and progression. Importantly,
use of the Core for the acquisition and analysis of ECGs, optical mapping (mouse atria and EHTs), and
characterization of Ca2+, action potential, and ion channel dynamics in isolated myocytes ensures uniform
methodology that will strengthen the individual Projects of this PPG. Furthermore, metabolic dynamics
measured in an electrophysiological context herein, will complement the same measured in a metabolic
context (Scientific Core 1). This Core will provide in-depth intellectual input to support Projects with
experimental design, execution and coordination of experiments, and centralization for data gathering, thereby
promoting interaction and integration between Projects beyond merely providing a service. Finally, this core
eliminates duplication of effort and optimizes the use of personnel, equipment, and supplies, which enables all
Projects on this PPG to achieve their scientific goals in an organized and cost-efficient manner. In sum, the
services provide by this core to the Projects will help advance the understanding of the pathophysiology of AF,
thereby supporting the main goal of this PPG to identify preventive and therapeutic strategies for AF and
advance them towards clinical application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Electrophysiology Scientific Core 2
-
批准号:10410646
-
项目类别:
-
资助金额:$26.24万
-
财政年份:2022
-
负责人:KENNETH LAURITA
-
依托单位:
Novel mechanisms and treatment of arrhythmia during resuscitation
-
批准号:9886863
-
项目类别:
-
资助金额:$66.9万
-
财政年份:2020
-
负责人:KENNETH LAURITA
-
依托单位:
Novel mechanisms and treatment of arrhythmia during resuscitation
-
批准号:10608116
-
项目类别:
-
资助金额:$63.62万
-
财政年份:2020
-
负责人:KENNETH LAURITA
-
依托单位:
Novel mechanisms and treatment of arrhythmia during resuscitation
-
批准号:10376229
-
项目类别:
-
资助金额:$63.62万
-
财政年份:2020
-
负责人:KENNETH LAURITA
-
依托单位:
A novel, multiparametric cardiac safety assay using human myocytes
-
批准号:8522876
-
项目类别:
-
资助金额:$1.3万
-
财政年份:2013
-
负责人:KENNETH LAURITA
-
依托单位:
A novel, multiparametric cardiac safety assay using human myocytes
-
批准号:8769228
-
项目类别:
-
资助金额:$19.2万
-
财政年份:2013
-
负责人:KENNETH LAURITA
-
依托单位:
Targeted cell therapy for the treatment of ventricular tachycardia
-
批准号:7825845
-
项目类别:
-
资助金额:$49.6万
-
财政年份:2009
-
负责人:KENNETH LAURITA
-
依托单位:
Targeted cell therapy for the treatment of ventricular tachycardia
-
批准号:7936150
-
项目类别:
-
资助金额:$47.66万
-
财政年份:2009
-
负责人:KENNETH LAURITA
-
依托单位:
Electrophysiological and antiarrhythmic benefit of cell therapy for heart disease
-
批准号:7588883
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:KENNETH LAURITA
-
依托单位:
Electrophysiological and antiarrhythmic benefit of cell therapy for heart disease
-
批准号:7255054
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:KENNETH LAURITA
-
依托单位:
Electrophysiological and antiarrhythmic benefit of cell therapy for heart disease
-
批准号:7788190
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:KENNETH LAURITA
-
依托单位:
Electrophysiological and antiarrhythmic benefit of cell therapy for heart disease
-
批准号:7407563
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:KENNETH LAURITA
-
依托单位:
Ca Handling & Arrhythmias Associated with LQT Syndrome
-
批准号:6828275
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2002
-
负责人:KENNETH LAURITA
-
依托单位:
Ca Handling & Arrhythmias Associated with LQT Syndrome
-
批准号:6620572
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2002
-
负责人:KENNETH LAURITA
-
依托单位:
Ca Handling & Arrhythmias Associated with LQT Syndrome
-
批准号:6689601
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2002
-
负责人:KENNETH LAURITA
-
依托单位:
Ca Handling & Arrhythmias Associated with LQT Syndrome
-
批准号:6419120
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2002
-
负责人:KENNETH LAURITA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: